Compare PRAX & CFR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PRAX | CFR |
|---|---|---|
| Founded | 2015 | 1868 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.6B | 8.1B |
| IPO Year | 2020 | N/A |
| Metric | PRAX | CFR |
|---|---|---|
| Price | $289.43 | $129.79 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 15 | 13 |
| Target Price | ★ $572.13 | $143.08 |
| AVG Volume (30 Days) | 308.0K | ★ 520.5K |
| Earning Date | 05-01-2026 | 04-30-2026 |
| Dividend Yield | N/A | ★ 3.09% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $9.72 |
| Revenue Next Year | $6,395.88 | $4.70 |
| P/E Ratio | ★ N/A | $14.55 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $26.70 | $100.31 |
| 52 Week High | $354.87 | $148.97 |
| Indicator | PRAX | CFR |
|---|---|---|
| Relative Strength Index (RSI) | 37.95 | 26.90 |
| Support Level | $266.93 | $124.76 |
| Resistance Level | $322.32 | $129.71 |
| Average True Range (ATR) | 16.36 | 3.29 |
| MACD | -4.02 | -1.08 |
| Stochastic Oscillator | 4.20 | 3.47 |
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.
Cullen/Frost is a regional US bank with around $53 billion in assets (as of September 2025), and it focuses exclusively on the Texas market. The bank has deep expertise in this market. It has implemented a relationship-based approach to banking that has garnered a strong market share in San Antonio. Cullen/Frost is also expanding into Houston, Dallas, and Austin market regions through branch openings. The bank's sweet spot is small to medium-size Texas-based commercial clients.